AlphAIalphai — Financial news for AI agents
yahoo.comAUG 272 min read$GMAB

Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?

Genmab (GMAB) raised its 2026 revenue guidance to $4.325B-$4.525B, up from $4.065B-$4.395B, citing strong royalty streams. H1 2026 revenue grew 25% YoY to $2.051B, with royalty revenue up 24%. Guggenheim raised its price target to $42. Hedge fund interest increased, with 30 funds holding positions in Q1 2026.

Original reporting
yahoo.com
Published Aug 27, 2026, 12:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 1:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle? — source image
Source · yahoo.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The guidance lift signals stronger cash flow and may attract growth‑oriented investors, but expense growth warrants caution.

02

Market read

Guidance raise is a primary catalyst for Genmab and could influence biotech royalty peers.

03

What to watch

Potential regulatory delays for epcoritamab and competitive pressures could limit royalty upside.

Relevance 8/10Novelty 8/10Timing: guidance released today

Background

Genmab is a Danish biotech that generates royalties from partnered oncology drugs and sells its own products.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab raised its full‑year 2026 revenue guidance to $4.325‑$4.525 billion, up from $4.065‑$4.395 billion.

Expected impact

Potential upside of 5‑10% if market digests the raise.

Evidence & confidence

Guidance lift is material, first disclosed, and reflects robust royalty streams and pipeline progress.

Market effects

Sector

Strengthens the biotech royalty sector and may lift peers with similar royalty models.

Regional

Positive for European‑listed biotech firms with US ADR exposure.

Global

Highlights continued demand for J&J‑partnered oncology assets.

Counterpoint

What could challenge this read

Higher guidance may be offset by rising operating expenses and leverage concerns.

Key entities

  • company
    Genmab A/S

    Biotech firm issuing the guidance.

  • partner
    Johnson & Johnson

    Partner whose DARZALEX sales drive Genmab royalties.

Read at source← All news

Related articles

AUG 7
$GMABMedAI 8/10

Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook

Genmab (GMAB) shares rose about 4.4% after the company reported first-half revenue up 25% to $2.05B, driven by royalty revenue up 24% to $1.71B. Management raised full-year revenue guidance to $4.325B-$4.525B and adjusted operating profit to $1.225B. Royalty strength was linked to Darzalex and Kesimpta, according to the article.

yahoo.com4 min
AUG 7
$GMABMedAI 9/10

Genmab (GMAB) Q2 2026 Earnings Call Transcript

Genmab’s Q2 2026 earnings call set full-year 2026 revenue guidance at $4.3 billion to $4.5 billion and operating profit at $1.1 billion to $1.4 billion. DARZALEX net trade sales were $4,207 million in Q2, with EPKINLY H1 sales $312 million and proprietary portfolio revenue $396 million. Management cited Merus integration, a 3.6% effective tax rate, and multiple late-2026 readouts.

fool.com6 min
AUG 6
$GMABHighAI 9/10

Genmab A/S: Genmab Announces Financial Results for the First Half of 2026

Genmab reported first-half 2026 revenue of $2,051 million, up 25% from $1,640 million a year earlier, driven by higher DARZALEX and Kesimpta royalties and higher EPKINLY net product sales. Royalty revenue rose to $1,708 million. Genmab updated 2026 guidance, citing higher DARZALEX royalties and EPKINLY net sales, and noted positive Phase 3 data for epcoritamab plus lenalidomide.

finanznachrichten.de7 min
JUL 23
$GMABMedAI 8/10

Genmab A/S and AbbVie: Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymph

Genmab (GMAB) and AbbVie (ABBV) clarified that in the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial of epcoritamab (Epcoritamab) for relapsed/refractory DLBCL, overall survival (OS) was the sole primary endpoint and was not met. The trial compares epcoritamab vs investigator’s choice chemotherapy. Results will be submitted for publication.

finanznachrichten.de4 min
JUL 23
$GMABMed

Globenewswire

Genmab (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) clarified Phase 3 EPCORE DLBCL-1 epcoritamab results. In the U.S., overall survival (OS) was the sole primary endpoint and was not met versus investigator’s choice chemoimmunotherapy (R-GemOx or BR) in relapsed/refractory DLBCL ineligible for transplant. Additional results will be submitted for publication.

via.ritzau.dk4 min